PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE This Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National...Patent License Agreement – Exclusive • November 20th, 2020 • AbCellera Biologics Inc. • Pharmaceutical preparations • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks), Appendix E (Commercialization Plan). Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).
RESEARCH COLLABORATION AND LICENSE AGREEMENT Between ABCELLERA BIOLOGICS INC. and ELI LILLY AND COMPANYCollaboration and License Agreement • November 20th, 2020 • AbCellera Biologics Inc. • Pharmaceutical preparations • New York
THIS RESEARCH COLLABORATION AND LICENSE AGREEMENT (the “Agreement”), effective as of the date this Agreement is duly executed by both Parties (the “Effective Date”), by and between ELI LILLY AND COMPANY, a corporation organized and existing under the laws of Indiana, with its principal business office located at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A. (“Lilly”) and ABCELLERA BIOLOGICS INC., a corporation organized under the laws of British Columbia, Canada, with its principle business office located at 2215 Yukon St., Vancouver, BC V5Y 0A1, Canada (“AbCellera”). AbCellera and Lilly are each referred to individually as a “Party” and together as the “Parties”.
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.AbCellera Biologics Inc. • November 20th, 2020 • Pharmaceutical preparations • British Columbia
I- The Strategic Innovation Fund (“SIF”) is designed to encourage research and development, and accelerate the technology transfer and commercialization of innovative products, services, and processes; facilitate the growth and expansion of firms; secure economically significant mandates within or to Canada; and, advance industrial research and technology demonstration activities through collaboration;
AGREEMENT AND PLAN OF MERGER among ABCELLERA US HOLDINGS INC. and MICKEY MERGER INC. and TRIANNI, INC. and FORTIS ADVISORS LLC and, solely for the purpose of Section 10.03, ABCELLERA BIOLOGICS INC. dated as of November 1, 2020Agreement and Plan of Merger • November 20th, 2020 • AbCellera Biologics Inc. • Pharmaceutical preparations • California
This Agreement and Plan of Merger (this “Agreement”), dated as of November 1, 2020, is entered into among AbCellera US Holdings Inc., a Delaware corporation (“Parent”), Mickey Merger Inc., a California corporation (“Merger Sub”), Trianni, Inc., a California corporation (the “Company”), Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as Holder Representative (the “Holder Representative”) and AbCellera Biologics Inc., solely for the purpose of Section 10.03 (the “Guarantor” and, together with Parent, Merger Sub, the Company and the Holder Representative, the “Parties” and each a “Party”).
CONFIDENTIAL S10-112 ● GSM, MW AMENDMENT 3/9/2017License Agreement • November 20th, 2020 • AbCellera Biologics Inc. • Pharmaceutical preparations
Effective the 22 day of March 2017, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and LINEAGE BIOSCIENCES, INC. (“Lineage”), a corporation having a principal place of business at 3183 Porter Drive, Palo Alto CA 94304, agree as follows:
OFFICE PREMISES LEASEOffice Premises Lease • November 20th, 2020 • AbCellera Biologics Inc. • Pharmaceutical preparations
AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • November 20th, 2020 • AbCellera Biologics Inc. • Pharmaceutical preparations • British Columbia
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made as of the 23rd day of March, 2020 among AbCellera Biologics Inc., a company existing under the laws of the Province of British Columbia (the “Company”) and the holders (the “Series A1 Holders”) of the Company’s Series A1 Preferred Shares (the “Series A1 Preferred Shares”) listed on Exhibit A hereto and the purchasers of the Company’s Series A2 Preferred Shares (the “Series A2 Preferred Shares”, and together with the Series A1 Preferred Shares, the “Preferred Shares”) listed on Exhibit A hereto or that subsequently become listed thereon in accordance with the terms hereof (collectively, the “Investors”).
LICENSE AGREEMENT Between: THE UNIVERSITY OF BRITISH COLUMBIA and ABCELLERA BIOLOGICS INC. SchedulesLicense Agreement • November 20th, 2020 • AbCellera Biologics Inc. • Pharmaceutical preparations • British Columbia
THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia with offices at #103-6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3
